Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenalidomide + liposomal doxorubicin
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Oral (lenalidomide)
01
Overview
**Lenalidomide + liposomal doxorubicin** is a combination regimen of lenalidomide, an immunomodulatory and anti-angiogenic small molecule, with liposomal doxorubicin, a nanoparticle-formulated anthracycline chemotherapy. Lenalidomide acts to enhance immune-mediated anti-tumor activity and inhibit tumor angiogenesis, while liposomal doxorubicin delivers doxorubicin in a pegylated-liposome nanoparticle to improve pharmacokinetics and reduce systemic toxicity. The combination is primarily investigated in relapsed/refractory or recurrent hematologic cancers such as multiple myeloma and in recurrent epithelial ovarian cancers, exhibiting synergistic anti-neoplastic effects and an acceptable safety profile as evidenced in early phase clinical studies[1][3].
- Other names
- lenalidomide plus liposomal doxorubicinlenalidomide and liposomal doxorubicinlenalidomide + pegylated liposomal doxorubicin
02
Targets
CK1α (Casein kinase I alpha)TOP2A (DNA topoisomerase II)IKZF1 (Ikaros family zinc finger protein 1)DNACRBN (Cereblon)IKZF3 (Zinc finger protein Aiolos)
Beyond the preview
Go deeper on lenalidomide + liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenalidomide + liposomal doxorubicin.